Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Uveal Melanoma 5Melanoma 3Select Advanced Solid Tumors 1Sarcoma, Clear Cell 1Sarcoma 1Nevus, Blue 1Neoplasm Metastasis 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × tebentafusp × 1 year × Clear all
NCT07057596 2026-03-06

NEO-TB

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting
19 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

NCT05315258 2025-07-17

TebeMRD

University of Oxford

Phase 2 Active not recruiting
850 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡